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CC BY-NC-ND license (http://creativeAbstract Y box binding protein-1 (YBX1) belongs to a DNA- and RNA-binding family of tran-
scription factors, containing the highly conserved cold shock domain (CSD). YBX1 is involved
in a number of cellular functions including transcription, translation, DNA damage repair
etc., and it is upregulated during times of environmental stress. YBX1 is localized in both
the cytoplasm and the nucleus. There, its nuclear translocation is observed in a number of can-
cers and is associated with poor prognosis and disease progression. Additionally, YBX1 expres-
sion is upregulated in a variety of cancers, pointing towards its role as a potential oncogene.
Under certain circumstances, YBX1 also promotes the expression of multidrug resistance 1
(MDR1) gene, which is involved in the development of drug resistance. Thus, it is critical to un-
derstand the mechanism of YBX1 regulation and its downstream effects on promoting cancer
development. A number of recent studies have highlighted the mechanisms of YBX1 regulation.
Mass spectrometric analyses have reported several post-translational modifications that
possibly play an important role in modulating YBX1 function. Phosphorylation is the most
widely occurring post-translational modification in YBX1. In vivo analyses of sites like S102
and more recently, S165 illustrate the relationship of post-translational regulation of YBX1
in promoting cell proliferation and tumor growth. This review provides a comprehensive and
up-to-date account of post-translational modifications identified in YBX1. This knowledge is
a key in allowing us to better understand the mechanism of YBX1 regulation, which will aidt of Pharmacology and Toxicology, Indiana University School of Medicine, 635 Barnhill drive, Indian-
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Y box binding protein 1 (YBX1) belongs to the YBX family of
transcription factors that contain an ancient and evolu-
tionarily conserved cold shock domain (CSD). The name
“cold shock” originates from E. coli, which, when exposed
to the stress of cold temperature, increases the expression
of around 13 proteins containing the CSD by 2e10 folds.
This helps the cell survive in low temperature.1 This
observation found in bacteria is similar to the role of YBX1
in eukaryotic cell’s response to stress, indicating the exis-
tence of not only structural, but also functional conserva-
tion over a wide evolutionary span in the YBX family.
The name ‘YBX’ was coined due to the ability of the YBX
protein family to bind the Y box sequence on DNA, defined
as 50-CTGATTGG-30. The YBX family of proteins has high
sequence homology across different species. There are
three members of the YBX family: YBX1, YBX2 and YBX3. As
shown in Fig. 1, all members have structural commonalities
as follows: an N-terminal alanine (A)- and proline (P)-rich
domain (A/P domain), a central CSD and a C-terminal
domain (CTD) consisting of alternating base/acid amino
acid repeats. The A/P domain is thought to be important for
the transcriptional activity of YBX1 and has also been shown
to interact with tumor suppressor p53 to mediate p53-
dependent transcription.2
The crystal structure of the human YBX1 CSD domain is
known to be comprised of a five-stranded anti-parallel-
barrel structure with a long flexible loop and has 40% ho-
mology with its bacterial counterpart.3 CSD has ribonu-
cleoprotein particle 1 (RNP1) and RNP2 recognition sites,
that mediate the site-specific interaction of YBX1 with DNA
and RNA. On the other hand, CTD also mediates non-
specific interactions with nucleic acids, especially with
single-stranded DNA. Additionally, CTD consists of a nuclear
localization signal and a cytoplasmic retention site. These
two sites regulate YBX proteins shuttling between nucleus
and cytoplasm.
As described above, YBX1, 2, and 3 are the three family
members that belong to the human YBX family. Differentng protein family. All three fam
minal domain, the highly conserYBX family members are encoded by different genes and
are localized on distinct chromosomes. For instance,
human YBX1 is encoded by the ybx1 gene present on
chromosome 1p34.2, while YBX2 is encoded by the ybx2
gene and is present on chromosome 17p13.1. On the other
hand, YBX3 is encoded by the ybx3 gene, which is present
on chromosome 12p13.1. Although YBX1, 2, and 3 share
structural similarity, they do not share similar functions.4
Human YBX1 is generally expressed in adult somatic cells
and is involved in the transcription of important genes that
participate in tumor development.4 This will be discussed in
the next section in detail. On the other hand, human YBX2
is expressed mainly in germ cells and is mainly involved in
the maintenance of stability and/or translation of germ cell
mRNAs. Human YBX3 is expressed during the embryonic
stage of development, but is absent in adult cells. YBX3 has
been shown to be a repressor of some growth factor pro-
moters, such as the GM-CSF promoter.5 Overall, YBX1, 2,
and 3 have important functions in almost all stages of the
cell life cycle and have important DNA- and RNA-binding
related functions.
In this review, we focus on the recent update regarding
the role of YBX1 in cancer, especially with respect to its
post-translational modifications. For broader knowledge
regarding YBX1, please refer to a relevant review
elsewhere.5Role of YBX1 in cancer
YBX1 is one of the most evolutionarily conserved nucleic
acid binding proteins. Initially, it was thought to bind only
the conserved Y-box element in double stranded DNA
(dsDNA). However, subsequent research has shown its
ability to bind to single stranded DNA (ssDNA), damaged
DNA, and RNA.5 In adult human cells, depending on its
localization, the functions and proteineprotein in-
teractions of YBX1 differ. Nuclear localization of YBX1
promotes the transcription of genes containing the Y box
consensus sequence in their promoter region.5 The targetily members, i.e. YBX1, YBX2 and YBX3 have common domains:
ved cold shock domain (CSD), and the C-terminal domain (CTD).
Table 1 Known and confirmed post-translational modifi-
cations in human YBX1.
Site on YBX1 Location in
YBX1 structure
Type of PTM Known
modulator
S10227 CSD Phosphorylation Akt
Y16231,33,34 CTD Phosphorylation FGFR1
Y188, Y28130 CTD Phosphorylation Unknown
S16529 CSD Phosphorylation Unknown
Akt: AKT8 virus oncogene cellular homolog; CSD: cold shock
domain; CTD: C-terminal domain; FGFR1: fibroblast growth
factor receptor 1.
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transcriptional regulation, mRNA packaging, and DNA
repair.6
YBX1 is also known to play important functions in cancer.
Its levels are increased in various types of cancer, including
cancers of the breast, colon, ovary, lung,7 prostate,8
stomach,9 etc. Furthermore, nuclear localization of YBX1
is also associated with a more aggressive phenotype of the
cancer and a poor survival rate.10,11 Thus, both high
expression levels and nuclear translocation of YBX1 in
cancer make YBX1 an ideal diagnosis marker and a possible
therapeutic target for cancer.12 To date, ample evidence
has been accumulated regarding the role of YBX1 in can-
cers. YBX1 is widely studied in the field of breast cancer
research. For instance, YBX1 is shown to be overexpressed
in about 40% of breast cancers, but absent in normal breast
tissue.13 This highlights the potential importance of YBX1 as
an oncogene in breast cancer. Davies et al showed that
YBX1 is capable of transforming normal human mammary
epithelial cells to cancerous cells via p300-mediated chro-
matin remodeling, leading to the formation of basal-like
breast cancer.14 Jung et al further reported that YBX1 is
important for sustaining the stem-like nature and tumori-
genic ability of a phenotypically distinct subset of breast
cancer cells. YBX1 carries out this function mainly through
the regulation of the sex determining region Y-box 2 gene
(Sox2), leading to a relatively more aggressive cancer sub-
type.15 Besides the potential mechanisms discussed above,
YBX1 also promotes breast cancer development by pre-
venting cancer cells from being eliminated by apoptosis.
For instance, YBX1 can interact with the tumor suppressor
p53, which causes an increase in the nuclear localization of
YBX1 and inhibits p53-dependent cell death, thus acting as
a negative regulator of apoptosis in breast cancer.16 YBX1
has also been implicated in other types of cancers. In
human non-small-cell lung cancers, YBX1 promotes the
transcription of cyclin D1, an oncogenic cyclin that pro-
motes cell growth.17 In human osteosarcoma cells, nuclear
expression of YBX1 regulates cell cycle progression at the
G1/S phase and not only promotes tumor growth, but is also
associated with a poor prognosis in these cases.18 Inter-
estingly, YBX1 also contributes to tumor metastasis and
growth through the epithelial-to-mesenchymal transition
(EMT) process. In prostate cancer, YBX1 promotes EMT,
leading to a more invasive form of this disease.19 In patients
with head and neck cancer, higher YBX1 expression is
associated with a lower disease-specific survival rate in
patients, supporting the association of YBX1 expression
with poor prognosis.20
Besides its role in more common cancer types described
above, YBX1 has also been shown to play a role in virus-
induced cancers. Human papillomaviruses are implicated in
cervical cancers and also in a subtype of head and neck
cancers. Leiprecht et al found that YBX1 plays a critical role
in papillomavirus-induced tumor formation by interacting
with the viral regulatory protein E2, leading to increased
expression of important oncogenes in rabbit keratinocyte
cell lines.21 Collectively, the accumulated evidence sup-
ports the critical role of YBX1 in cancer development in
both non-virus and virus-induced cancers.
The multi-faceted effects of YBX1 in cancer are also
reflected by its important role in cancer chemotherapydrug resistance.22,23 Elevated levels of YBX1 have been
associated with resistance to chemotherapy drugs in
different types of cancers. This is a great challenge to cli-
nicians, as it limits their ability to control disease pro-
gression and to improve patient survival. Various studies
have highlighted novel factors that can be targeted to
reduce YBX1-based drug resistance. For instance, YBX1
plays an important role in the chemotherapy drug taxane’s
resistance in ovarian cancer cells. It is reported that the
focal adhesion kinase (FAK), a non-receptor tyrosine kinase
that usually promotes cell growth, is involved in the regu-
lation of YBX1-dependent drug resistance.24 Inhibition of
FAK causes increased sensitivity to taxane by decreasing
YBX1 phosphorylation and YBX1 nuclear accumulation in an
Akt-dependent manner.23 In addition to taxane resistance,
expression of YBX1 is also shown to confer resistance to
cisplatin treatment in ovarian cancer cells.22
In addition to chemotherapy drug resistance, YBX1
also plays an important role in stress-induced drug
resistance. One such important drug resistance gene regu-
lated by YBX1 is the multi-drug resistance 1 (MDR1) gene.
MDR1 has Y box in its promoter region. It was observed
that during environmental stress, YBX1 caused the
increased expression of MDR1, leading to environmental
stress-dependent drug resistance.24 Basaki et al showed
that Akt-mediated nuclear translocation of YBX1 is impor-
tant for acquiring drug resistance through upregulation of
MDR1 in human ovarian cancer cells.25 Knockdown of YBX1
also resulted in increased sensitization to DNA-damaging
agents and ionizing radiation, thus suggesting it might
exert protective effects against cytotoxic DNA-damaging
agents in human colon cancer cells.26 Therefore, certain
functions of YBX1, like managing the stress response, can
also contribute to drug resistance in response to environ-
mental factors.
Taken together, YBX1 plays an essential and unique role
in cancer progression, chemotherapy drug resistance, and
environmental factors related to its cytoprotective effects.
Post-translational modifications in YBX1
Like many other transcription factors, the activity and
function of YBX1 is regulated at multiple levels. Recent
emerging evidence has demonstrated that the functions of
YBX1 can be regulated by post-translational modifications
at various sites. As illustrated in Table 1 and Fig. 2, several
post-translational modification sites with important
Figure 2 Regulation and functions of YBX1. YBX1 can be
regulated by post-translational modifications like phosphory-
lation, ubiquitylation, acetylation and methylation. This af-
fects the downstream functions of YBX1 that mediate a variety
of cellular processes including DNA repair, transcription,
translation, pre-mRNA splicing, mRNA packaging and mRNA
stability.
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in vivo.
Phosphorylation
Confirmed phosphorylation sites on YBX1
The first phosphorylation site identified was serine 102
(S102) in the CSD region of YBX1 (Table 1).27 This is also the
most extensively studied site in YBX1. Sutherland et al
showed that mutating S102 of YBX1 to alanine (A)
decreased tumor growth in breast cancer, strongly sug-
gesting that S102 phosphorylation is critical for the onco-
genic activity of YBX in breast cancer. Phosphorylation at
S102 may promote the YBX1 oncogenic ability by facilitating
nuclear translocation of YBX1 and enhancing its binding to
DNA. Furthermore, it was reported that the level of phos-
phorylated S102 positively correlates with EGFR (epidermal
growth factor receptor) and HER2 (human epidermal
growth factor receptor 2) expression: both are upregulated
in primary breast cancer specimens. On the other hand,
S102A-YBX1 mutant prevented induction of both EGFR and
HER2 and showed decreased tumor growth in breast
cancer.28
In addition to phosphorylation of S102 in breast cancer, a
recent study by our lab underlines the significance of the
novel phosphorylation of S165 in the CSD region of YBX1
(Table 1).29 We provided the first evidence regarding the
important connection between YBX1 and the nuclear factor
kappa B (NF-kB). We suggest that YBX1 functions as a po-
tential NF-kB activator. Using mass spectrometry (MS)
analysis, we identified novel phosphorylation of S165 on
YBX1. Overexpression of the S165A-YBX1 mutant in either
293 cells or colon cancer HT29 cells showed dramatically
reduced NF-kB activating ability as compared to that of wt
YBX1, confirming that S165 phosphorylation is critical for
the activation of NF-kB by YBX1. We also showed that
expression of the S165A-YBX1 mutant significantly
decreased expression of NF-kB-inducible genes, reducedcell growth, and compromised tumorigenic ability as
compared to wt YBX1. Taken together, we proved that YBX1
functions as a tumor promoter via NF-kB activation, and
that phosphorylation of S165 of YBX1 is critical for this
function. Therefore, our important discovery may lead to
blocking S165 phosphorylation as a potential therapeutic
strategy to treat colon cancer.
Other YBX1 phosphorylation sites have also been iden-
tified. Using deletion constructs of YBX1, von Roeyen et al
identified two additional phosphorylation sites, tyrosine
188 (Y188) and Y281 in the CTD domain of YBX1 (Table 1).
Using site-specific antibodies, they proved that phosphor-
ylation of Y281, but not Y188 in YBX1 takes place and ap-
pears to correlate with nuclear protein shuttling of YBX1 in
undifferentiated human monocytic THP-1 cells.30 Kasyapa
et al reported that fibroblast growth factor receptor 2
(FGFR2), a receptor tyrosine kinase, can interact with
YBX1, leading to the phosphorylation of tyrosine 162 (Y162)
in the CTD of YBX1 in atypical myeloproliferative disorders
(Table 1).31 This finding suggests that tyrosine phosphory-
lation of YBX1 may play an important role in the develop-
ment of this devastating disease, in which FGFR2 has been
widely implicated.
Predicted but unconfirmed phosphorylation sites on
YBX1
As described above, very few phosphorylation sites on
YBX1 have been confirmed in vivo. However, as shown in
Table 2, multiple potential sites have been identified by MS
analysis, but have yet to be confirmed by in vivo
experiments.30,32e38
Several research groups carried out MS analyses to
identify substrates of various kinases and other cellular
factors in the proteomes of normal human as well as cancer
cell lines. For instance, Blasius et al used MS analysis to
identify substrates of cell-cycle checkpoint kinase 1 (Chk1),
which plays an essential role in controlling cellular pro-
cesses such as DNA replication, mitosis, and response to
DNA-damage. One of the substrates Chk1 phosphorylates is
threonine 80 (T80), which is present in the CSD domain of
YBX1.39 Regulation of YBX1 by Chk1 seems plausible since
the functions of both Chk2 and YBX1 are mostly similar and
it is possible that Chk1 exerts some of its effects through
post-translationally modifying YBX1. However, the function
of T80 is yet to be confirmed in vivo.
The most recent advancement can be seen in the study
by Sharma et al. In this study, a large-scale quantitative
MS study of phosphoproteome in cervical cancer HeLa cells
allowed for global identification of protein modifica-
tions.40 Among the various proteins that were modified,
several sites were also found in YBX1 (Table 2). All the
phosphorylation sites that were identified in this study
were mostly in the A/P and CTD domains. The majority of
these sites have never been defined before. Thus, this
study opens an extensive area of research to explore the
importance of these sites in contribution to cervical
cancer.
It is worth noting that until these sites are confirmed by
in vivo experiments, they are simply potential sites.
Nevertheless, this information could guide any future
endeavor to better understand the role of post-
translational modifications in YBX1 regulation.
Table 2 Predicted but unconfirmed post-translational modifications in human YBX1.
Site on YBX1 Location in
YBX1 structure
Type of PTM Known
modulator
Reference
Residues 262e32444 CTD Ubiquitylation RBBP6 Chibi et al 2008
S174, S17632,40 CTD Phosphorylation EGF Pan et al 2009, Sharma et al 2014
K8145 CSD Acetylation e Choudhary et al 2009
S16733,40 CTD Phosphorylation Ionizing
Radiation
Bennetzen et al 2010, Sharma et al 2014
T8039 CSD Phosphorylation Chk1 Blasius et al 2011
S136, T27134 CTD Phosphorylation e Kettenbach et al 2011
K64, K11843 CSD Ubiquitylation e Wagner, et al 2011
K81, K92, K93, K13741,43 CSD Ubiquitylation e Kim et al 2011, Wagner et al 2011
K26441,42 CTD Ubiquitylation e Shi et al 2011, Kim et al 2011
T10837 CSD Phosphorylation e Stokes et al 2012
Y15838 CTD Phosphorylation e Trost et al 2012
Y196, S20835 CTD Phosphorylation e Bai et al 2012
S313, S31428,40 CTD Phosphorylation RIP-3 Wu et al 2012, Sharma et al 2014
S2, S3, T7, S21, S32, S36, S4440 A/P domain Phosphorylation e Sharma et al 2014
T8940 CSD Phosphorylation e Sharma et al 2014
R199, R200, R23947 CTD Mono-methylation e Guo et al 2014
A/P domain: alanine- and proline-rich domain; Chk1: cell-cycle checkpoint kinase 1; CSD: cold shock domain; CTD: C-terminal domain;
EGF: epidermal growth factor; RBBP6: retinoblastoma binding protein 6; RIP-3: receptor-interacting protein kinase 3.
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Data from Sharma et al and others suggest that YBX1 could
be potentially modified at multiple amino acid residues.
Besides the phosphorylation described above, other modi-
fications on YBX1 include ubiquitylation, acetylation, cas-
pase cleavage and methylation (Table 2).40
Ubiquitylation
Ubiquitylation is a type of post-translational modification
that controls various cellular processes through proteaso-
mal degradation of target proteins. As listed in Table 2,
some potential ubiquitylation sites have been identified on
YBX1. Notably, three studies employed genome wide mass
spectrometric proteomics to scan for ubiquitylation in the
genome and found several sites on YBX1.41e43 Chibi et al
identified that retinoblastoma binding protein 6 (RBBP6),
an E3 ubiquitin ligase, interacts with YBX1, leading to
ubiquitylation and proteasomal degradation of YBX1.44
Thus, dysregulation of ubiquitylation may alter YBX1 func-
tion and further contribute to its oncogenic capability, and
hence is worth exploring in future in vivo studies.
Acetylation
In 2009, Choudhary et al carried out a study using MS
analysis to scan for global lysine acetylation sites in whole
cell lysates from human acute myeloid leukemia cell lines.
Among the 3600 lysine (K) acetylation sites found on 1750
proteins, one of them was K81 in the CSD domain of YBX1.
Current evidence suggests that lysine acetylation is
important for functions and interactions of various genes
including p53.45 It is also known that p53 and YBX1 interact
with each other and that nuclear localization of YBX1 can
be regulated only by functional but not mutant p53.2,46
Therefore, it would be worthwhile to confirm K81 acetyla-
tion in vivo, and to explore whether it affects theinteraction between YBX1 and p53 or other proteins in the
cell, and further, how the acetylation may modulate cell
function in vivo.
Methylation
Methylation of proteins occurring at lysine and arginine (R) is
also one of the most critical post-translational modifications
seen in nature. Methylation of proteins has been implicated
in a number of cellular processes like gene transcription,
DNA damage and repair, protein translocation etc. As shown
in Table 2, YBX1 is methylated at residues R199, 200 and 239
using immunoaffinity purification of methylated peptides
followed by MS analysis.47 Interestingly, previous work from
our laboratory also showed that the transcription factor NF-
kB ismethylated on K218/221 andR30 of its p65 subunit.48e50
Since we found that YBX1 is a direct activator of NF-kB,29 it
would be interesting to further examine whether methyl-
ation of YBX1 plays an important role in regulating the
interaction between YBX1 and NF-kB, contributing to
dysfunction of these two proteins in cancer. This possibility
further justifies the necessity of confirming the methylation
sites of YBX1 in vivo.
Perspective
Post-translational modification is an important way to
regulate protein function. Different sites on a single protein
allow for triggering varied functions of the same protein,
depending on the cellular requirements and/or environ-
mental stimuli. This allows for fine-tuning of the protein
function. YBX1 has emerged as one of the proteins sub-
stantially post-translationally modified, as identified by
advanced mass spectrometric proteomics (Tables 1 and 2).
This vast amount of information makes post-translational
modification of YBX1 an exciting research area for further
exploration.
Post translational modifications of YBX1 in cancer 245Based on the fact that many post-translational modifi-
cation sites have been identified on YBX1, while few were
confirmed in vivo, an obvious and immediate task that
scientists are facing is to confirm most if not all of the
identified sites in vivo. If confirmed, the important bio-
logical role of each modified site can be further examined
in cancer or other YBX1 related diseases. Another daunting
task once the modification site is confirmed is that efforts
need to be put into the discovery of the enzymes that may
catalyze these specific modifications. Often, enzymes are
better targets in the development of drugs to treat cancer.
Furthermore, as cutting edge technologies emerge at an
amazing pace, it should not come as a major surprise that
more post-translational modification sites will be discov-
ered on YBX1 in the near future. Moreover, post-
translational modification of proteins is often cellular-
context dependent. It is not difficult to imagine that
quite different modifications of YBX1 could be identified in
different types of cancer and disease states. These unique
post-translational modifications of YBX1 could represent a
disease-specific signature which may help with diagnosis
and treatment of that specific disease.
To conclude, understanding the fascinating state of
post-translational modification of YBX1 will not only lead to
a better understanding of the mechanisms underlying bio-
logical processes regulated by YBX1, but will also help to
develop effective pathway-specific therapeutic strategies
against YBX1 in different types of cancer and YBX1-related
diseases.
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